Masterclone

Masterclone is a Russian biotechnology company founded in 2006 by Aleksandr Mikhailovich Shuster, specializing in the discovery and development of novel therapeutic monoclonal antibodies and recombinant proteins. The company serves as a critical research and development engine within the broader Pharmstandard and Generium pharmaceutical ecosystems. Masterclone's technological capabilities are anchored by its strategic licensing of the PER.C6 human cell line platform from Crucell and DSM Biologics, which facilitates the high-yield production of complex biologics. The company has engaged in significant international collaborations, notably a strategic alliance with Affitech to develop a pipeline of human antibodies, including the anti-VEGF candidate AT001 for oncology. Additionally, Masterclone holds intellectual property for innovative anti-diabetic compositions, reflecting its commitment to addressing unmet needs in oncology, immunology, and metabolic diseases.